There is a large body of evidence available to support xenon's safety, efficacy and neuroprotective characteristics. Most recently, a positive Phase II clinical trial demonstrated a statistically significant reduction in brain tissue damage and a trend towards better survival outcomes in PCAS resulting from an OHCA.
Learn more about Xenon and its extensive body of evidence as a neuroprotectant.
Research and Development
Our R&D initiatives are initially focused on the use of XENEX as a neuroprotectant in post-cardiac arrest syndrome (PCAS) patients.
Following a successful in-hospital PCAS study, the focus will move to PCAS in a pre-hospital emergency response setting. This opens the door to future indications in therapeutic areas such as Stroke, Traumatic Brain Injury, Anaesthesia Induced Developmental Neurotoxicity and Hypoxic Ischaemic Encephalopathy.